Strategic Diagnostics appoints new CFO
This article was originally published in Clinica
Custom antibody producer Strategic Diagnostics has appointed Kevin Bratton CFO and vice-president of finance. Before this, Mr Bratton was senior vice-president of business operations for EUSA Pharma, and previously to that, was senior vice-president and CFO of Cytogen, before it was acquired by EUSA Pharma in May 2008. He has over 35 years of experience in multinational financial operations across the healthcare, biotechnology and technology industries. Newark, Delaware-based Strategic Diagnostics provides monoclonal and polyclonal antibodies, and contract assay development services for the diagnostic and biotechnology markets, among others. It also manufactures kits for food safety, environmental and water quality testing.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.